Abstract
In the recent years many advances have been achieved in the field of the treatment of lung cancer; with the development of novel therapeutic pathways due to the knowledge of oncologic drivers involved in the carcinogenesis of the lung, as well as the involvement of new radiotherapic and surgical techniques. Nevertheless, the standard treatment for elderly is still debated, mainly because of an underrepresentation of elderly patients in clinical trials. Herein we try to summarize the main guidelines for the treatment of lung cancer, with particular attention for the elderly patients, what we know and what has changed.
Keywords: Lung Cancer, non-small cell lung cancer, small cell lung cancer, elderly patients, surgery, radiotherapy, chemotherapy, adjuvant treatment, locally advanced nsclc, metastatic lung cancer, clinical trials, multimodality treatment, cutoff point, geriatric oncology, comprehensive geriatric assessment.
Anti-Cancer Agents in Medicinal Chemistry
Title:Treatment of Elderly Patients Affected by Lung Cancer: Why to Treat, when to Treat and what we Know
Volume: 13 Issue: 9
Author(s): Alessandra Bearz, Massimiliano Berretta, Arben Lleshi, Eleonora Berto and Umberto Tirelli
Affiliation:
Keywords: Lung Cancer, non-small cell lung cancer, small cell lung cancer, elderly patients, surgery, radiotherapy, chemotherapy, adjuvant treatment, locally advanced nsclc, metastatic lung cancer, clinical trials, multimodality treatment, cutoff point, geriatric oncology, comprehensive geriatric assessment.
Abstract: In the recent years many advances have been achieved in the field of the treatment of lung cancer; with the development of novel therapeutic pathways due to the knowledge of oncologic drivers involved in the carcinogenesis of the lung, as well as the involvement of new radiotherapic and surgical techniques. Nevertheless, the standard treatment for elderly is still debated, mainly because of an underrepresentation of elderly patients in clinical trials. Herein we try to summarize the main guidelines for the treatment of lung cancer, with particular attention for the elderly patients, what we know and what has changed.
Export Options
About this article
Cite this article as:
Bearz Alessandra, Berretta Massimiliano, Lleshi Arben, Berto Eleonora and Tirelli Umberto, Treatment of Elderly Patients Affected by Lung Cancer: Why to Treat, when to Treat and what we Know, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (9) . https://dx.doi.org/10.2174/18715206113136660353
DOI https://dx.doi.org/10.2174/18715206113136660353 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
miR-122 is a Unique Molecule with Great Potential in Diagnosis, Prognosis of Liver Disease, and Therapy Both as miRNA Mimic and Antimir
Current Gene Therapy Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells
Mini-Reviews in Medicinal Chemistry Is α7-nAChR a Possible Target for Lung Cancer and Malignant Pleural Mesothelioma Treatment?
Current Drug Targets Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy Novel Insights in Molecular Mechanisms of CLL
Current Pharmaceutical Design Respiration and Energy Homeostasis
Current Respiratory Medicine Reviews Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Editorial (Thematic Issue: Advances in Drug Discovery for the Treatment of Cancer: Many Approaches, One Goal)
Current Topics in Medicinal Chemistry Innovative formulations for controlled drug delivery to the lungs and the technical and toxicological challenges to overcome<sup>#</sup>
Current Pharmaceutical Design CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response
Current Gene Therapy An Update of Radiolabeled Bombesin Analogs for Gastrin-Releasing Peptide Receptor Targeting
Current Pharmaceutical Design Antineoplastic Activities, Apoptotic Mechanism of Action and Structural Properties of a Novel Silver(I) Chelate
Current Medicinal Chemistry The Urokinase Receptor and its Structural Homologue C4.4A in Human Cancer: Expression, Prognosis and Pharmacological Inhibition
Current Medicinal Chemistry In-silico Evidences of Regulatory Roles of WT1 Transcription Factor Binding Sites on the Intervening Sequences of the Human Bcl-2 Gene
Current Bioinformatics Sleep Disturbances in Lung Cancer Patients
Current Respiratory Medicine Reviews MicroRNAs: An Apparent Switch for High-Altitude Pulmonary Edema
MicroRNA Cytotoxicity of Novel Sulfanilamides Towards Sensitive and Multidrugresistant Leukemia Cells
Current Medicinal Chemistry Aberrant Immunoglobulin Variations as Indicators of Eventual Clonal Changes in Symptomatic Multiple Myeloma Patients' Course
Current Cancer Therapy Reviews Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets (1→3)-α-D-Glucans from Aspergillus spp.: Structural Characterization and Biological Study on their Carboxymethylated Derivatives
Current Drug Targets